These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 28558956)

  • 21. An increase of interleukin-33 serum levels after coronary stent implantation is associated with coronary in-stent restenosis.
    Demyanets S; Tentzeris I; Jarai R; Katsaros KM; Farhan S; Wonnerth A; Weiss TW; Wojta J; Speidl WS; Huber K
    Cytokine; 2014 Jun; 67(2):65-70. PubMed ID: 24725541
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Preprocedural red blood cell distribution width predicts bare metal stent restenosis.
    Yildiz A; Tekiner F; Karakurt A; Sirin G; Duman D
    Coron Artery Dis; 2014 Sep; 25(6):469-73. PubMed ID: 24614629
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical analysis of lectin-like oxidized low-density lipoprotein receptor-1 in patients with in-stent restenosis after percutaneous coronary intervention.
    Liu J; Liu Y; Jia K; Huo Z; Huo Q; Liu Z; Li Y; Han X; Wang R
    Medicine (Baltimore); 2018 Apr; 97(17):e0366. PubMed ID: 29702981
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Role of Gene Polymorphisms/Haplotypes and Plasma Level of TGF-β1 in Susceptibility to In-Stent Restenosis Following Coronary Implantation of Bare Metal Stent in Chinese Han Patients.
    Chen HJ; Mo N; Zhang YF; Su GZ; Wu HD; Pei F
    Int Heart J; 2018 Jan; 59(1):161-169. PubMed ID: 29332922
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Platelet Distribution Width on Admission Predicts In-Stent Restenosis in Patients with Coronary Artery Disease and Type 2 Diabetes Mellitus Treated with Percutaneous Coronary Intervention.
    Hu CP; Du Y; Zhu Y; Shi C; Qin Z; Zhao YX
    Chin Med J (Engl); 2018 Apr; 131(7):757-763. PubMed ID: 29578117
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Use of the neutrophil to lymphocyte ratio for prediction of in-stent restenosis in bifurcation lesions.
    Balli M; Taşolar H; Çetin M; Tekin K; Çağliyan ÇE; Türkmen S; Yilmaz M; Elbasan Z; Şahin DY; Çayli M
    Eur Rev Med Pharmacol Sci; 2015 May; 19(10):1866-73. PubMed ID: 26044233
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The adipokine vaspin is associated with decreased coronary in-stent restenosis in vivo and inhibits migration of human coronary smooth muscle cells in vitro.
    Kastl SP; Katsaros KM; Krychtiuk KA; Jägersberger G; Kaun C; Huber K; Wojta J; Speidl WS
    PLoS One; 2020; 15(5):e0232483. PubMed ID: 32392256
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Serum levels of bilirubin as an independent predictor of coronary in-stent restenosis: a new look at an old molecule.
    Kuwano T; Miura S; Shirai K; Ike A; Mori K; Shimizu T; Zhang B; Iwata A; Nishikawa H; Kawamura A; Saku K
    J Atheroscler Thromb; 2011; 18(7):574-83. PubMed ID: 21427507
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Effects of miRNA-1,miRNA-21 in plasma on in-stent restenosis in patients with coronary heart disease and diabetes mellitus after percutaneous coronary intervention].
    Guan JJ; Zhang Y; Liu YJ
    Zhongguo Ying Yong Sheng Li Xue Za Zhi; 2018 Apr; 34(4):304-308 384. PubMed ID: 30788936
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Association of the Endothelial Nitric Oxide Synthase Gene T786C Polymorphism with In-Stent Restenosis in Chinese Han Patients with Coronary Artery Disease Treated with Drug-Eluting Stent.
    Zeng WP; Zhang R; Li R; Luo JF; Hu XF
    PLoS One; 2017; 12(1):e0170964. PubMed ID: 28129392
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prognostic Value of Type D Personality for In-stent Restenosis in Coronary Artery Disease Patients Treated With Drug-Eluting Stent.
    Wang Y; Liu G; Gao X; Zhao Z; Li L; Chen W; Tao H; Yu B; Lin P
    Psychosom Med; 2018 Jan; 80(1):95-102. PubMed ID: 28938244
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Low basal levels of circulating adiponectin in patients undergoing coronary stenting predict in-stent restenosis, independently of basal levels of inflammatory markers: lipoprotein associated phospholipase A2, and myeloperoxidase.
    Moldoveanu E; Mut-Vitcu B; Tanaseanu GR; Marta DS; Manea G; Kosaka T; Vidulescu C; Tanaseanu C
    Clin Biochem; 2008 Dec; 41(18):1429-33. PubMed ID: 18930040
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Intravascular Ultrasound and Angiographic Predictors of In-Stent Restenosis of Chronic Total Occlusion Lesions.
    Kang J; Cho YS; Kim SW; Park JJ; Yoon YE; Oh IY; Yoon CH; Suh JW; Youn TJ; Chae IH; Choi DJ
    PLoS One; 2015; 10(10):e0140421. PubMed ID: 26465755
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Intravascular ultrasound assessment of optimal stent area to prevent in-stent restenosis after zotarolimus-, everolimus-, and sirolimus-eluting stent implantation.
    Song HG; Kang SJ; Ahn JM; Kim WJ; Lee JY; Park DW; Lee SW; Kim YH; Lee CW; Park SW; Park SJ
    Catheter Cardiovasc Interv; 2014 May; 83(6):873-8. PubMed ID: 22815193
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical and procedural predictors of suboptimal outcome after the treatment of drug-eluting stent restenosis in the unprotected distal left main stem: the Milan and New-Tokyo (MITO) registry.
    Takagi K; Ielasi A; Shannon J; Latib A; Godino C; Davidavicius G; Mussardo M; Ferrarello S; Figini F; Carlino M; Montorfano M; Chieffo A; Nakamura S; Colombo A
    Circ Cardiovasc Interv; 2012 Aug; 5(4):491-8. PubMed ID: 22851528
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Long-Term Clinical Outcomes After Bioresorbable Vascular Scaffold Implantation for the Treatment of Coronary In-Stent Restenosis: A Multicenter Italian Experience.
    Moscarella E; Ielasi A; Granata F; Coscarelli S; Stabile E; Latib A; Cortese B; Tespili M; Tanaka A; Capozzolo C; Caliendo L; Colombo A; Varricchio A
    Circ Cardiovasc Interv; 2016 Apr; 9(4):e003148. PubMed ID: 27059683
    [TBL] [Abstract][Full Text] [Related]  

  • 37. An increase of VEGF plasma levels is associated with restenosis of drug-eluting stents.
    Katsaros KM; Kastl SP; Krychtiuk KA; Hutter R; Zorn G; Maurer G; Huber K; Wojta J; Christ G; Speidl WS
    EuroIntervention; 2014 Jun; 10(2):224-30. PubMed ID: 24168783
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Association of increased serum CTRP5 levels with in-stent restenosis after coronary drug-eluting stent implantation: CTRP5 promoting inflammation, migration and proliferation in vascular smooth muscle cells.
    Shen Y; Li C; Zhang RY; Zhang Q; Shen WF; Ding FH; Lu L
    Int J Cardiol; 2017 Feb; 228():129-136. PubMed ID: 27863353
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical presentation and outcomes of coronary in-stent restenosis across 3-stent generations.
    Magalhaes MA; Minha S; Chen F; Torguson R; Omar AF; Loh JP; Escarcega RO; Lipinski MJ; Baker NC; Kitabata H; Ota H; Suddath WO; Satler LF; Pichard AD; Waksman R
    Circ Cardiovasc Interv; 2014 Dec; 7(6):768-76. PubMed ID: 25466551
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prognostic Value of Plasma Long Noncoding RNA ANRIL for In-Stent Restenosis.
    Wang F; Su X; Liu C; Wu M; Li B
    Med Sci Monit; 2017 Oct; 23():4733-4739. PubMed ID: 28970468
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.